Traditional Chinese medicine in the treatment of patients with hyperuricemia: A randomized placebo‐controlled double‐blinded clinical trial

Author:

Leong Pui‐Ying1234ORCID,Chen Huang‐Hsi2,Gau Shuo‐Yan15ORCID,Chen Chia‐Yin26,Su Yi‐Chang789,Wei James Cheng‐Chung21011ORCID

Affiliation:

1. School of Medicine Chung Shan Medical University Taichung Taiwan

2. Institute of Medicine Chung Shan Medical University Taichung Taiwan

3. Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine Chung Shan Medical University Hospital Taichung Taiwan

4. PhD Program of Business Feng‐Chia University Taichung Taiwan

5. Institute of Medical Education Chi Mei Medical Center Tainan Taiwan

6. Chinese Medicine Clinical Trial Center Chung Shan Medical University Hospital Taichung Taiwan

7. National Research Institute of Chinese Medicine, Ministry of Health and Welfare Taipei Taiwan

8. Graduate Institute of Chinese Medicine, College of Chinese Medicine China Medical University Taichung Taiwan

9. Chinese Medical Advancement Foundation Taipei Taiwan

10. Division of Allergy, Rheumatology and Immunology, Department of Internal Medicine Chung Shan Medical University Hospital Taichung Taiwan

11. Graduate Institute of Integrated Medicine China Medical University Taichung Taiwan

Abstract

AbstractBackgroundStudies have demonstrated the association of hyperuricemia with hypertension, metabolic syndrome, cardiovascular disease, and chronic renal disease. Although Western medicine presents promising effects for treating hyperuricemia and gout, identifying a safe and effective alternative to traditional Chinese medicine (TCM) for treating hyperuricemia is essential.ObjectiveTo evaluate the efficacy and safety of TCM formulas, “Wu‐Ling San” and “Yin Chen Wu‐Ling San,” in patients with hyperuricemia.MethodsA randomized, double‐blinded, placebo‐controlled clinical trial in adults with hyperuricemia was conducted. Sixty patients with serum urate level higher than 8 mg/dL were enrolled in the study. Patients were then randomized into three arms: “Wu‐Ling San,” “Yin Chen Wu‐Ling San,” and placebo for 4 weeks. Efficacy and safety were evaluated at weeks 2, 4, and 8. Primary and secondary endpoints were set to evaluate the serum urate concentration and related indicators at weeks 2, 4, and 8.ResultsNo significant differences were observed among the three arms in terms of the serum urate level (<6 mg/dL) at week 4. The serum urate level was lower in the “Yin Chen Wi‐Ling” arm at week 8 (8.1 mg/dL vs. 9.1 mg/dL, p = .034). The serum urate levels were significantly different in both the “Wu‐Ling San” and “Yin Chen Wu‐Ling San” arms from those at the baseline (p < .05).ConclusionsTwo TCM formulas were found to be relatively safe for the short‐term treatment of the patients with hyperuricemia. No statistically significant difference was observed in reaching the target–serum urate level <6 mg/dL.

Publisher

Wiley

Subject

Rheumatology

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3